Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure.

Trial Details

NCT ID
NCT07602049
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Cryoablation therapy + anti-PD-1 antibody
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
  • Age≥14 years old, and≤70 years old ;
  • Pathologically diagnosed as soft tissue sarcomas, and staging for advanced or unresectable patients ;
  • Patients with standard treatment (such as chemotherapy) failure ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →